Report: DEA did too little to constrain opioid supply even as crisis escalated
DEA's poor oversight led the agency to increase opioid manufacturing quotas with little regard to drug misuse, according to a new report from a government watchdog.
WASHINGTON — The Drug Enforcement Administration fell dramatically short in regulating the prescription opioid supply over the past two decades — even as the country’s addiction and overdose crisis escalated, according to a new report from the Justice Department’s inspector general.
As prescription levels and demand for pain drugs rose, the agency continued to raise manufacturing quotas for opioids with little
